DOSING DETAILS   

Study Dosing Objective:  Effective Dose, Safety Profile

Established Protocol:  Effective dose with adverse effects

Route of Administration: 

Cannabinoid Ratio:  (CBD : CBG)   35 : 50    

Dosage Form:  cannabidiol(CBD; 35 mg) cannabigerol (CBG; 50 mg) beta-caryophyllene (BCP; 25 mg) branched-chain amino acids (BCAAs; 3.8 g) magnesium citrate (420 mg)

Dosing Regimen:  Participants consumed the formulation twice per day

Treatment Duration:  3.5 days

Clinical Relevance:  The tested formulation improved function and reduced interference of delayed onset muscle soreness on daily activities.

Adverse Events:  One adverse event in the active group (diarrhea) and two in the placebo (dry mouth; eye rash/swollen eye).

Citation: